Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569027 | 0.85 | ADRA1D (0.40) | ADRA1DADRA1AADRA1BCACNA1B | |
| SCHEMBL5568028 | 0.84 | HTT (0.40) | ADRA1DADRA1AADRA1BCACNA1BFNTA | |
| SCHEMBL5568481 | 0.84 | ADRA1D (0.39) | ADRA1DADRA1AADRA1BCACNA1BLMNA | |
| SCHEMBL6471458 | 0.84 | NPC1 (0.45) | ADRA1DADRA1AADRA1BCACNA1BLMNA | |
| SCHEMBL5563153 | 0.83 | ADRA1D (0.39) | ADRA1DADRA1AADRA1BCACNA1B | |
| SCHEMBL5563397 | 0.82 | NPY5R (0.44) | ADRA1DADRA1AADRA1BCACNA1BFNTA | |
| SCHEMBL5569023 | 0.81 | HTT (0.42) | ADRA1DADRA1AADRA1BCACNA1B | |
| SCHEMBL5567175 | 0.80 | HTT (0.40) | ADRA1DADRA1AADRA1BCACNA1BFNTA | |
| SCHEMBL6471949 | 0.80 | MAPT (0.46) | ADRA1DADRA1AADRA1BCACNA1BLMNA | |
| SCHEMBL5563109 | 0.80 | ADRA1D (0.40) | ADRA1DADRA1AADRA1BCACNA1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | claimed |
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | claimed |
| WO-2005009392-A2 | DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-03 | — | — | WO | claimed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | disclosed |
| WO-2005009392-A2 | DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | CACNA1E, CACNA1C, CACNA1S | ADRA1D 170/4885ADRA1A 175/4885ADRA1B 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.